A potential anti-coagulant role of complement factor H

Molecular Immunology

Volumn 59, Issue 2, 2014, Pages 188-193

  Ferluga, Janez ^a,b   Kishore, Uday ^b   Sim, Robert B ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b BRUNEL UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anti phospholipid syndrome; Coagulation; Complement; Factor H

Indexed keywords

BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 12; CARDIOLIPIN; COMPLEMENT FACTOR H; PHOSPHATIDIC ACID; PHOSPHATIDYLSERINE;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURFACE PROPERTY;

ANTI-PHOSPHOLIPID SYNDROME; COAGULATION; COMPLEMENT; FACTOR H;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION; CARDIOLIPINS; COMPLEMENT FACTOR H; FACTOR XII; HUMANS; PHOSPHATIDIC ACIDS; PHOSPHATIDYLSERINES; PHOSPHOLIPIDS; THROMBOSIS;

EID: 84896042815     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.02.012     Document Type: Article

References (61)

1. Amaral M., Favas C., Delgado Alves J. Persistency of low levels of anticardiolipin and anti-beta2 glycoprotein 1 in thrombosis. European Journal of Internal Medicine 2010, 21:101-103.
2. Arvieux J., Pernod G., Regnault V., Darnige L., Garin J. Some anticardiolipin antibodies recognize a combination of phospholipids with thrombin-modified antithrombin, complement C4b-binding protein, and lipopolysaccharide binding protein. Blood 1999, 93:4248-4255.
3. Barthel D., Schindler S., Zipfel P.F. Plasminogen is a complement inhibitor. Journal of Biological Chemistry 2012, 287:18831-18842.
4. Clark S.J., Higman V.A., Mulloy B., Perkins S.J., Lea S.M., Sim R.B., Day A.J. His-384 allotypic variant of Factor H associated with age-related macular degeneration has different heparin binding properties from the non-disease-associated form. Journal of Biological Chemistry 2006, 28:24713-32720.
5. Dahlback B. C4b-binding protein: a forgotten factor in thrombosis and hemostasis. Seminars in Thrombosis and Hemostasis 2011, 37:355-361.
6. Dal Ben E.R.R., Hartmann do Prado C., Babtista T.S.A., Bauer M.E., Staub H.L. Decreased levels of circulating CD4+CD25+Foxp3+ regulatory T cells in patients with primary antiphospholipid syndrome. Journal of Clinical Immunology 2013, 33:876-879.
7. de Groot P.G., Urbanus R.T. The significance of antoantibodies against β2-glycoprotein 1. Blood 2012, 120:266-274.
8. de Groot P.G., Urbanus R.T., Roest M. Platelet interacton with the vessel wall. Antiplatelet Agents, Handbook of Experimental Pharmacology 210 2012, Springer-Verlag, Berlin Heidelberg. 10.1007/978-3-642-29423-5-4. P. Gresele (Ed.).
9. de Laat B., Pengo V., Pabinger I., Musial J., Voskuyl E., Bulting I.E.M., Ruffatti A., Rozman B., Kveder T., de Moerloose P., Boehlen F., Rand J., Ulcova-Gallova z., Mertens K., de Groot P.G. The association between circulating antibodies against domain 1 of beta2-glycoprotein 1: an international multicenter study. Journal of Thrombosis and Haemostasis 2009, 7:1767-1773.
10. de Laat B., de Groot P.G., Derksen R.H.W.M., Mertens K., Rosendaal F.R., Doggen C.J.M. Association between beta2-glycoprotein 1 plasma levels and the risk of myocardial infarction in older men. Blood 2009, 114:3656-3661.
11. Ferluga J., Yu B.B., Guerin J., Jackson J., Sim R.R. Similarities between complement factor H and β2 glycoprotein 1: phospholipid binding and autoantibodies. Molecular Immunology 1998, 35:375.
12. Ghebrehiwet B., Randazzo B.P., Dunn J.T., Silverberg M., Kaplan A.P. Mechanism of activaton of the classical pathway of complement by Hageman Factor fragment. Journal of Clinical Investigation 1983, 71:1450-1456.
13. Gropp K., Weber N., Reuter M., Micklisch S., Kopka I., Hallstromm T., Skerka C. B2-glycoprotein 1, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood 2011, 118:2774-2783.
14. Gulla K.C., Gupta K., Krarup A., Gal P., Schwaeble W.J., Sim R.B., O'Connor C.D., Hajela K. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology 2009, 2009:482-495.
15. Guerin J., Feighery C., Sim R.B., Jackson J. Antibodies to β2-glycoprotein 1-a specific marker for the antiphospholipid syndrome. Clinical and Experimental Immunology 1997, 109:304-309.
16. Guerin J., Sim R.B., Feighery C., Jackson J. Antibody recognition of complement regulatory proteins, Factor H, CR1, and C4bp in antiphospholipid syndrome patients. Lupus 1998, 7(abstract supplement 2):S180.
17. Guerin J., Sim R., Yu B.-B., Ferluga J., Feighery C., Jackson J. Heterogeneous recognition of beta 2-glycoprotein 1 by antibodies from anti-phospholipid syndrome patients. Thrombosis and Haemostasis 2000, 84:374-380.
18. Hakobyan S., Tortajada A., Harris C.L., de Cordoba S.R., Morgan B.P. Variant-specific quantification of factor H in plasma reveals null alleles associated with atypical hemolytic uremic syndrome. Kidney International 2010, 78:782-788.
19. 2-macroglobulin. Methods in Enzymology 1976, 45:639-652.
20. Huber-Lang M., Sarma J.V., Zetoune F.S., Tittirsch D., Neff T.A., McGuire S.R., Lambris J.D., Warner R.L., Flierl M.A., Hoesel L.M., Gebhard F., Younger J.G., Drouin S.M., Wetsel R.A., Ward P.A. Generation of C5a in the absence of C3: a new complement activation pathway. Nature Medicine 2006, 12:682-687.
21. Hughes G.R.V. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. British Medical Journal 1983, 287:1088-1089.
22. Johnstone A.P., Thorpe R. Immunochemistry in Practice 1996, Wiley-Blackwell, Oxford, ISBN 978-0-86542-633-7 April 1996. third ed.
23. + cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003, 421:388-392.
24. 2-glycoportein 1 to cardiolipin. Biochemical Journal 1995, 310:315-321.
25. Kishore U., Sim R.B. Factor Has a regulator of the classical pathway activation. Immunobiology 2012, 217:162-168.
26. Levi M., van der Poll T., Schultz M. New insights into pathways that determine the link between infection and thrombosis. The Netherlands Journal of Medicine 2012, 70:114-120.
27. Licht C., Weyersberg A., Heinen S., Stapenhorst L., Devenge J., Beck B., Waldherr R., Kirschfink M., Zipfel P.F., Hoppe B. Successful plasma therapy for atypical haemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. American Journal of Kidney Diseases 2005, 45. 425-421.
28. Matsuura E., Igarashi Y., Fugimoto M., Ichikawa K., Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. The Lancet 1990, 336:177-178.
29. McNeil H.P., Simpson R.J., Chesterman C.N., Krilis S.A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein 1 (apolipoprotein H). Proceedings of the National Academy of Sciences of the United States of America 1990, 87:4120-4124.
30. Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. European Journal of Internal Medicine 2013, 24:496-502.
31. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey L., Cervera R., Derksen R.H.W.M., de Groot P.G., Koike T., Meroni P.L., Reber G., Shoenfeld Y., Tincani A., Vlachoyiannopoulos P.G., Krilis S.A. International concensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis 2006, 4:295-306.
32. Muller F., Mutch N.J., Schenk W.A., Smith S.A., Esteri L., Spronk H.M., Schmidbauer S., Gahl W.A., Morrissey J.H., Renne T. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009, 139:1143-1156.
33. Musial J. Antiphospholipid antibodies and thrombosis. Thrombosis Research 2012, 129:345-347.
34. Nimpf J., Bevers E.M., Bomans P.H.H., Till U., Wurm H., Kostner G.M., Zwaal R.F.A. Prothrombinase activity of human platelets is inhibited by β2-glycoprotein 1. Biochimica et Biophysica Acta 1986, 884:142-149.
35. Nimpf J., Wurm H., Kostner G.M. Beta2-glycoprotein 1 (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987, 63:109-114.
36. Ochoa E., Iriondo M., Bielsa A., Ruiz-Irastorza G., Estonba A., Zubiaga A.M. Thrombotic antiphospholipid syndrome shows a strong haplotypic association with SH2B3-ATXN2 locus. PLoS One 2013, 8(7):e67897.
37. Oikonomopoulou K. Interactions between coagulation and complement-their role in inflammation. Seminars in Immunopathology 2012, 34(1):151-165.
38. Oku K., Atsumi T., Bohgaki M., Amengual O., Kataoka H., Horita B., Yasuda S., Koike T. Complement activation in patients with primary antiphospholipid syndrome. Annals of the Rheumatic Diseases 2009, 68:1030-1035.
39. Peerschke E.I.B., Yin W., Grigg S.E., Ghebrehiwet B. Blood platelets activate the classical pathway of human complement. Journal of Thrombosis and Haemostasis 2006, 4:2035-2042.
40. Pierangeli S.S., Vega-Ostertag M., Liu X., Girardi G. Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome. Annals of the New York Academy of Sciences 2005, 1051:413-420.
41. Puurunen M., Jokiranta S., Vaarala O., Meri S. Lack of functional similarity between complement factor H and anticardiolipin cofactor, beta 2-glycoprotein I (apolipoprotein H). Scandinavian Journal of Immunology 1995, 42(5):547-550.
42. Redecha P., Tilley R., Tencati M., Salmon J.E., Kirchofer D., Mackman N., Girardi G. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody-induced fetal injury. Blood 2007, 110:2423-2431.
43. Rehman A.A., Ahsan H., Khan F.H. Alpha-2-macroglobulin: a physiological guardian. Journal of Cellular Physiology 2013, 228:1665-1675.
44. Renne T., Schmaier A.H., Nickel K.F., Blomback M., Maas C. In vivo roles of factor XII. Blood 2012, 120:4296-4303.
45. Richards A., Kemp E.J., Liszewski M.K., Goodship J.A., Lampe A.K., Cecorte R., Muslumanoglu M.H., Kavukcu S., Filler G., Pirson Y., Wen L.S., Atkinson J.P., Goodship H.J. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial haemolytic uremic syndrome. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:12966-12971.
46. Ripoche J., Day A.J., Harris T.J.R., Sim R.B. The complete aminosequence of human complement factor H. Biochemical Journal 1988, 249:593-602.
47. Rodriguez de Cordoba S., Esparza-Gordillo J., de Jorge E.G., Lopez-Trascasa M., Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease association. Molecular Immunology 2004, 41:355-367.
48. Rojkjaer R., Schousboe I. The surface-dependent autoactivation mechanism of factor XII. European Journal of Biochemistry 1997, 243:160-166.
49. Saito A. Plasma kallikrein is activated on dermatan sulphate and cleaves factor H. Biochemical and Biophysical Research Communications 2008, 370:646-650.
50. Schousboe I. Beta 2-glycoportein 1: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985, 66:1085-1091.
51. Schousboe I. In vitro activation of the contact activation system (Hageman factor system) in plasma by acidic phospholipids and the inhibitory effect of β2-glycoprotein 1 on this activation. International Journal of Biochemistry 1988, 20:309-315.
52. r kininogen. European Journal of Biochemistry 1990, 193:495-499.
53. Sim R.B., Day A.J., Moffatt B.E., Fontain M. Complement factor I and cofactors in control of complement system convertase enzymes. Methods in Enzymology 1993, 223:13-36.
54. Steinkasserer A., Estaller C., Weiss E.H., Sim R.B., Day A.J. Complete nucleotide and deduced amino acid sequence of human β2-glycoprotein 1. Biochemical Journal 1991, 277:387-391.
55. Sheng Y., Reddel S.W., Herzog H., Wang Y.X., Brighton T., France M.P., Robertson S.A., Krilis S.A. Impaired thrombin generation in β2-glycoprotein 1 null mice. The Journal of Biological Chemistry 2001, 276:13817-13821.
56. Tan L.A., Yu B., Sim F.C.J., Kishore U., Sim R.B. Complement activation by phospholipids: the interplay of factor H and C1q. Protein Cell 2010, 1:1033-1049.
57. Tavoosi N., Smith S.A., Davis-Harrison R.L., Morrissey J.H. Factor VII and protein C are phosphatidic acid-binding proteins. Biochemistry 2013, 52:5545-5552.
58. Tripodi A., de Groot P.G., Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. Journal of Internal Medicine 2011, 270:110-122.
59. Vazquez-Mellado J., Llorente L., Richaud-Patin Y., Alarcon-Segovia D. Exposure of anionic phospholipids upon platelet activation permits binding of β2 glycoprotein 1 and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. Journal of Autoimmunity 1994, 7:335-348.
60. Williams S.C., Sim R.B. Dye-ligand affinity purification of human complement factor B and beta 2 glycoprotein 1. Journal of Immunological Methods 1993, 157:25-30.
61. Zadura A.F., Zipfel P.F., Bokarewa M.I., Sturfelt G., Jonsen A., Nilsson S.C. Factor H autoantibodies and deletion of complement factor H-related protein -1 in rheumatic diseases in comparison to atypical haemolytic uremic syndrome. Arthritis Research & Therapy 2012, 14:R187.